Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 September 2022 | Story André Damons | Photo André Damons
Sithembiso Ndlovu
Sithembiso Ndlovu is a lecturer in the Dean’s Office, Faculty of Health Sciences who recently completed his research into the impact the COVID-19 pandemic had on gender-based violence (GBV) among women.

A lecturer at the University of the Free State (UFS) Faculty of Health Sciences hopes his research into the impact the COVID-19 pandemic had on gender-based violence (GBV) among women, could assist the victims and especially government and organisations to address this evil post-COVID-19. 

Sithembiso Ndlovu, a Public Health Lecturer in the Division of Public Health, Office of the Dean of Health Sciences, says this research was a narrative review paper which aimed to explore the impact of the COVID-19 pandemic on GBV among women since there is inadequate established literature on this topic, particularly in South Africa. The focus was on intimate partner violence.

He started working on the review in February 2021 and finished in August the same year where after the paper was published by the African Journal of Reproductive Health (AJRH) in July 2022. He says he believes his research aligns with the UFS narrative of creating opportunities and growth through leading, learning and teaching, focused research, and impactful engagement with society given the quality of the research that his review upholds. 

Looking at the state and impact of GBV

Says Ndlovu: “I believe my research will be impactful in academia and in the lives of women who experienced GBV during lockdown. The study will also be impactful to women who will experience GBV in the future through recommended interventions, which I believe government departments and various GBV-oriented organisations can adopt to curb the increase in GBV cases in the country post-COVID-19 pandemic. 

”All in all, the research expresses the notion of care for the well-being of South African women who are voiceless or powerless and thus creates an opportunity for them to be able to seek help.”

The researcher says he wanted to look at the state and impact of GBV among women during the pandemic in the South African context and lay a foundation for prospective interventions to mitigate the increase of GBV cases during the lockdown. He envisages government departments and local organisations that deal with issues relating to GBV to consider the proposed interventions. 

“Also, it remains vital to engage men on the importance of GBV and the role they can play in decreasing the prevalence of this second pandemic after the COVID-19 as President Cyril Ramaphosa noted,” says Ndlovu.

According to him, without proper and accessible support, there will always be an increased risk of victimisation, even in households where there was no violence before the lockdown. Multipronged and all-inclusive intervention strategies are needed to address the prevalence of GBV cases effectively and sufficiently in South Africa. 

What does the research show? 

Ndlovu says the research found that there are multiple factors that contributed to the surge in GBV cases in South Africa, including alcohol availability and consumption, job losses, financial dependence, psychological distress, and emotional imbalances during the lockdown. During the restrictive lockdown, women were more exposed to the aggressors at home, where varying hostile power dynamics prevail, leaving the victims with limited opportunity to find any potential help and support due to limited mobility.

“When I was drafting the paper, there was limited literature on GBV during COVID-19 and comparing and contrasting statistics between the two periods was challenging. At the start of lockdown in March 2020, 87 000 cases of GBV and interpersonal violence were reported, a significant increase compared to pre-COVID-19. 

“However, the reports did not specify the type of interpersonal violence, and GBV reported or the gender of the aggressor although it has been widely reported that male partners perpetrate most IPV.” 

Interventions

Ndlovu wrote in the research article that key intervention strategies in combating GBV and ensuring that victims are supported adequately include dialogues and interventions around high-level communication and behaviour change programmes, prioritisation of reported cases, and developing interventions tailored to respond to the economically vulnerable circumstances women encounter. 

“There should be an emergency strengthening of the support systems that could be utilised by women experiencing violence and who are planning to escape the violent environment during regulated lockdown curfew periods in South Africa.

“Interventions should also include denormalising violence against women by their male counterparts and men in general. This could be implemented through educational programmes in communities, including schools where violence is prevalent. In this regard, an evaluation study on a school violence programme in Tshwane found that the programme increased positive knowledge of violence and attitudes toward violence. The recommended services must also be offered in all South African official languages to ensure that information is received and understood extensively,” he wrote. 

GBV-related programmes need to be prioritised in every sector and government department. This would necessitate realistic measures and activities to ensure impact. Governments must collaborate with various organisations to derive interventions by eliminating factors contributing to a surge in GBV cases. 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept